JP2012021005A5 - - Google Patents

Download PDF

Info

Publication number
JP2012021005A5
JP2012021005A5 JP2011177316A JP2011177316A JP2012021005A5 JP 2012021005 A5 JP2012021005 A5 JP 2012021005A5 JP 2011177316 A JP2011177316 A JP 2011177316A JP 2011177316 A JP2011177316 A JP 2011177316A JP 2012021005 A5 JP2012021005 A5 JP 2012021005A5
Authority
JP
Japan
Prior art keywords
equol
medicament
androgen
androgen receptor
providing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011177316A
Other languages
English (en)
Japanese (ja)
Other versions
JP5535999B2 (ja
JP2012021005A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2012021005A publication Critical patent/JP2012021005A/ja
Publication of JP2012021005A5 publication Critical patent/JP2012021005A5/ja
Application granted granted Critical
Publication of JP5535999B2 publication Critical patent/JP5535999B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2011177316A 2002-10-29 2011-08-12 アンドロゲンによって仲介される疾患を治療するためのエクオールの使用 Expired - Fee Related JP5535999B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42246902P 2002-10-29 2002-10-29
US60/422,469 2002-10-29

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2004548591A Division JP4889944B2 (ja) 2002-10-29 2003-10-29 アンドロゲンによって仲介される疾患を治療するためのエクオールの使用

Publications (3)

Publication Number Publication Date
JP2012021005A JP2012021005A (ja) 2012-02-02
JP2012021005A5 true JP2012021005A5 (enExample) 2012-10-11
JP5535999B2 JP5535999B2 (ja) 2014-07-02

Family

ID=32230355

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2004548591A Expired - Lifetime JP4889944B2 (ja) 2002-10-29 2003-10-29 アンドロゲンによって仲介される疾患を治療するためのエクオールの使用
JP2011177316A Expired - Fee Related JP5535999B2 (ja) 2002-10-29 2011-08-12 アンドロゲンによって仲介される疾患を治療するためのエクオールの使用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2004548591A Expired - Lifetime JP4889944B2 (ja) 2002-10-29 2003-10-29 アンドロゲンによって仲介される疾患を治療するためのエクオールの使用

Country Status (6)

Country Link
US (7) US20060122262A1 (enExample)
EP (1) EP1569636B1 (enExample)
JP (2) JP4889944B2 (enExample)
AU (1) AU2003286781B2 (enExample)
CA (1) CA2504682A1 (enExample)
WO (1) WO2004039327A2 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0313182A (pt) * 2002-07-24 2007-07-24 Childrens Hosp Medical Center composições e produtos contendo equol enantiomérico
US8668914B2 (en) * 2002-07-24 2014-03-11 Brigham Young University Use of equol for treating skin diseases
AU2003286781B2 (en) 2002-10-29 2009-05-21 Brigham Young University Use of equol for treating androgen mediated diseases
US8580846B2 (en) 2002-10-29 2013-11-12 Brigham Young University Use of equol for ameliorating or preventing neuropsychiatric and neurodegenerative diseases or disorders
ES2417481T3 (es) * 2003-06-30 2013-08-08 Otsuka Pharmaceutical Co., Ltd. Composición que contiene una bacteria del ácido láctico que produce ecuol
EP1740191A4 (en) * 2004-04-28 2008-07-30 Univ Brigham Young USE OF EQUOL FOR THE TREATMENT OF SKIN DISEASES
CN101253270B (zh) * 2005-07-29 2012-02-29 卡尔皮斯株式会社 更年期障碍预防·改善剂及功能性饮食品
US7528267B2 (en) 2005-08-01 2009-05-05 Girindus America, Inc. Method for enantioselective hydrogenation of chromenes
NL1030571C2 (nl) * 2005-12-01 2006-04-27 Sara Lee De Nv Geurafgiftesysteem.
US8680140B2 (en) * 2006-08-02 2014-03-25 University Of Southern California Phytoestrogenic formulations for alleviation or prevention of menopausal symptoms
JP2010501485A (ja) * 2006-08-18 2010-01-21 ブリガム・ヤング・ユニバーシティ 神経精神医学的または神経変性的な疾患または障害を予防または治療するためのエクオルの使用
WO2008126752A1 (ja) * 2007-04-09 2008-10-23 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo エクオール類を有効成分とする美白剤
AU2008262870B2 (en) * 2007-06-13 2013-07-11 Otsuka Pharmaceutical Co., Ltd. Equol-containing extract, method for production thereof, method for extraction of equol, and equol-containing food
EP2320889A4 (en) * 2008-08-15 2016-09-21 Nestec Sa METHOD FOR INCREASING THE CHANGE OF ENERGY REPLACEMENT
US20110091435A1 (en) * 2008-10-24 2011-04-21 University Of Southern California Phytoestrogenic formulations for alleviation or prevention of hair loss
EP2898923A3 (en) * 2011-04-15 2015-10-07 Nestec S.A. Isoflavones for regulating sirtuin gene expression
AU2012245639B2 (en) * 2011-04-20 2016-06-30 Nestec S.A. Methods and compositions suitable for preventing and treating hyperleptinemia
KR20160026042A (ko) * 2014-08-29 2016-03-09 (주)아모레퍼시픽 락토비온산을 함유하는 항스트레스용 또는 항상성 유지용 조성물
AU2015333634B2 (en) * 2014-10-14 2020-04-30 Ausio Pharmaceuticals, Llc Anhydrous crystalline form of S-equol
US10391079B2 (en) * 2016-07-26 2019-08-27 Ausio Pharmaceuticals, Llc Methods of diagnosing and treating Alzheimer's disease with S-equol
WO2019240872A1 (en) 2018-06-15 2019-12-19 The Board Of Regents Of The University Of Texas System Methods of treating and preventing melanoma with s-equol
EP3806846A1 (en) 2018-06-15 2021-04-21 Board of Regents, The University of Texas System Methods of treating and preventing breast cancer with s-equol
CA3176547A1 (en) * 2020-04-23 2021-10-28 Milad ROUHIMOGHADAM Gper proteolytic targeting chimeras
JPWO2021235278A1 (enExample) * 2020-05-21 2021-11-25
WO2022050308A1 (ja) * 2020-09-04 2022-03-10 株式会社ダイセル Ｎａｍｐｔ遺伝子発現増強用組成物
CN116531393A (zh) * 2023-04-03 2023-08-04 河北医科大学 一种预防高热惊厥发作的药物组合物
JP7596493B1 (ja) * 2023-11-24 2024-12-09 株式会社ダイセル 男性のｑｏｌの改善のための組成物

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4390559A (en) * 1979-04-11 1983-06-28 Z-L Limited Partnership Isoflavones and related compounds, methods of preparing and using and antioxidant compositions containing same
US5468501A (en) 1982-09-01 1995-11-21 Hercon Laboratories Corporation Article useful for administration of pharmacologically-active substances transdermally, orally or by means of implant
USRE34457E (en) * 1983-12-28 1993-11-30 Daicel Chemical Industries, Inc. Separating agent
GB8626344D0 (en) * 1986-11-04 1986-12-03 Zyma Sa Bicyclic compounds
JPH02124883A (ja) 1988-11-04 1990-05-14 Kitasato Inst:The 抗酸化作用を有するイソフラボン誘導体およびその製造法
CH679584A5 (enExample) * 1989-11-10 1992-03-13 Nestle Sa
TW279133B (enExample) 1990-12-13 1996-06-21 Elan Med Tech
USRE40792E1 (en) * 1992-05-19 2009-06-23 Novogen Research Pty Ltd Health supplements containing phyto-oestrogens, analogues or metabolites thereof
AU6635994A (en) * 1993-04-16 1994-11-08 Tufts University School Of Medicine Method for treatment of menopausal and premenstrual symptoms
US5613958A (en) 1993-05-12 1997-03-25 Pp Holdings Inc. Transdermal delivery systems for the modulated administration of drugs
US5320949A (en) * 1993-10-12 1994-06-14 Protein Technologies International, Inc. Process for producing aglucone isoflavone enriched vegetable protein fiber
US5424331A (en) * 1994-06-10 1995-06-13 Bio-Virus Research Incorporated Pharmaceutical compositions and dietary soybean food products for the prevention of osteoporosis
WO1996010341A1 (en) 1994-10-03 1996-04-11 Schouten Industries B.V. Food and health products
US5523087A (en) * 1995-02-15 1996-06-04 Bio-Virus Research Incorporated Pharmaceutical compositions for the treatment of diabetic male sexual dysfunction
AUPN166195A0 (en) * 1995-03-13 1995-04-06 Norvet Research Pty Limited Process for glucan extraction
FR2731706B1 (fr) * 1995-03-14 1997-04-11 Cird Galderma Composes heterocycliques aromatiques, compositions pharmaceutiques et cosmetiques les contenant et utilisations
US5554519A (en) 1995-08-07 1996-09-10 Fermalogic, Inc. Process of preparing genistein
US5693018A (en) 1995-10-11 1997-12-02 Science Incorporated Subdermal delivery device
US5821361A (en) * 1996-06-11 1998-10-13 Protein Technologies International, Inc. Recovery of isoflavones from soy molasses
AUPO203996A0 (en) * 1996-08-30 1996-09-26 Novogen Research Pty Ltd Therapeutic uses
US5726034A (en) * 1996-09-06 1998-03-10 Protein Technologies International, Inc. Aglucone isoflavone enriched vegetable protein extract and protein material, and high genistein and daidzein content materials and process for producing the same
US6020471A (en) * 1996-09-13 2000-02-01 Abbott Laboratories Process for isolating phytoestrogens from plant protein
US5804234A (en) * 1996-09-13 1998-09-08 Suh; John D. Plant protein for nutritional products and method of making same
WO1998021946A1 (en) 1996-11-18 1998-05-28 Internutria, Inc. Composition and treatment for persistent reproductive transition symptoms
US5733926A (en) * 1996-12-13 1998-03-31 Gorbach; Sherwood L. Isoflavonoids for treatment and prevention of alzheimer dementia and reduced cognitive functions
AUPO427196A0 (en) 1996-12-19 1997-01-23 University Of Sydney, The A method for preventing or controlling cataract
US6146668A (en) * 1997-04-28 2000-11-14 Novogen, Inc. Preparation of isoflavones from legumes
AU7165798A (en) * 1997-04-28 1998-11-24 Anticancer, Inc. Use of genistein and related compounds to treat certain sex hormone related conditions
EP0979074A4 (en) * 1997-05-01 2003-07-09 Novogen Inc TREATMENT OR PREVENTION CLIMATE ACTION SYMPTOMS AND OSTEOPOROSIS
US6083526A (en) * 1997-05-22 2000-07-04 Gorbach; Sherwood L. Use of isoflavonoids in the treatment or prevention of postpartum depression
US6060070A (en) * 1997-06-11 2000-05-09 Gorbach; Sherwood L. Isoflavonoids for treatment and prevention of aging skin and wrinkles
WO1999007392A1 (en) * 1997-08-08 1999-02-18 Otsuka Pharmaceutical Co., Ltd. Isoflavone-containing compositions
US6521433B1 (en) * 1997-09-17 2003-02-18 E. I. Du Pont De Nemours And Company cDNA sequences from plants that encode activities associated with isoflavone biosynthesis
US5855892A (en) * 1997-09-19 1999-01-05 Potter; Susan M. Method for decreasing LDL-cholesterol concentration and increasing HDL-cholesterol concentration in the blood to reduce the risk of atherosclerosis and vascular disease
US5952374A (en) * 1997-09-29 1999-09-14 Protein Technologies International, Inc. Method for inhibiting the development of Alzheimer's disease and related dementias- and for preserving cognitive function
US5942539A (en) * 1997-10-03 1999-08-24 Wake Forest University Methods of treating or preventing endometriosis with phytoestrogens
AUPP112497A0 (en) * 1997-12-24 1998-01-22 Novogen Research Pty Ltd Compositions and method for protecting skin from UV induced immunosupression and skin damage
US5958946A (en) * 1998-01-20 1999-09-28 Styczynski; Peter Modulation of hair growth
US6004558A (en) * 1998-02-25 1999-12-21 Novogen, Inc. Methods for treating cancer with legume plant extracts
AUPP260798A0 (en) * 1998-03-26 1998-04-23 Novogen Research Pty Ltd Treatment of medical related conditions with isoflavone containing extracts of clover
US6086915A (en) 1998-04-01 2000-07-11 Bioresponse L.L.C. Compositions and methods of adjusting steroid hormone metabolism through phytochemicals
EP1082122A4 (en) 1998-05-27 2003-04-09 Sherwood L Gorbach Isoflavonoids for treatment and prevention of migraine headaches
WO2000013661A1 (en) 1998-09-10 2000-03-16 Avon Products, Inc. Method and compositions for reducing dermatological aging and for reducing bruising
HK1041634A1 (zh) * 1998-11-25 2002-07-19 Nutri Pharma Asa 含大豆蛋白、食用纤维及植物性雌激素混合物的成份，以及使用上述成份预防及/或治疗肺部疾病
CA2352510A1 (en) 1998-11-25 2000-06-02 Nutri Pharma Asa Composition comprising soy protein, dietary fibres and a phytoestrogen compound and use thereof in the prevention and/or treatment of type 2 diabetes, the metabolic syndrome and associated cardiovascular diseases
WO2000041491A2 (en) 1999-01-15 2000-07-20 Nutrahealth Ltd (Uk) Modified food products and beverages, and additives for food and beverages
AUPP868599A0 (en) 1999-02-15 1999-03-11 Novogen Research Pty Ltd Production of isoflavone derivatives
KR20010108509A (ko) * 1999-04-16 2001-12-07 다비드 에 질레스 에스트로겐 수용체-β리간드
US6592910B1 (en) 1999-04-20 2003-07-15 Board Of Trustees, Southern Illinois University Methods of treating clinical diseases with isoflavones
US6544566B1 (en) * 1999-04-23 2003-04-08 Protein Technologies International, Inc. Composition containing plant sterol, soy protein and isoflavone for reducing LDL cholesterol
MXPA01011291A (es) 1999-05-04 2003-07-14 American Home Prod Derivados de urea ciclica y amida ciclica.
US6159959A (en) * 1999-05-06 2000-12-12 American Home Products Corporation Combined estrogen and antiestrogen therapy
US6401125B1 (en) 1999-08-05 2002-06-04 Nextpage, Inc. System and method for maintaining state information between a web proxy server and its clients
US6375994B1 (en) * 1999-08-20 2002-04-23 Sun Ten Laboratories, Inc. Preparation of fiber, L-glutamine and a soy derivative for the purpose of enhancement of isoflavone bioavailability
WO2001095901A1 (en) * 2000-06-14 2001-12-20 Alla Shapiro Radioprotective agents
US6455568B2 (en) * 2000-07-06 2002-09-24 Wyeth Combination therapy for inhibiting sphincter incontinence
AU2001273125A1 (en) 2000-07-06 2002-01-21 American Home Products Corporation Combinations of bisphosphonates, estrogenic agents and optionally estrogens
CA2414060A1 (en) 2000-07-06 2002-01-17 Wyeth Combinations of statins, estrogenic agents and optionally estrogens
AU2001271784A1 (en) 2000-07-06 2002-01-21 Wyeth Therapy for prosthesis-related bone degeneration
AU2001283322A1 (en) 2000-08-10 2002-02-18 M. D. Brian D. Zelickson Organic nutrient for hair loss treatment
US6326366B1 (en) * 2000-08-22 2001-12-04 Protein Technologies International Hormone replacement therapy
US20020143059A1 (en) 2000-12-28 2002-10-03 Sreekumar Pillai Skin care product containing retinoids, retinoid booster and phytoestrogens in a dual compartment package
US6565864B2 (en) * 2000-12-28 2003-05-20 Unilever Home & Personal Care Usa, A Division Of Conopco, Inc. Skin care product containing retinoids and phytoestrogens in a dual compartment package
US20020192310A1 (en) 2001-02-02 2002-12-19 Bland Jeffrey S. Medical composition for managing hormone balance
ATE556155T1 (de) * 2001-02-02 2012-05-15 Cons Eng Co Inc Verfahren zur herstellung und wärmebehandlung einer mehrzahl von metallgusteilen
EP1234572B1 (de) * 2001-02-26 2013-10-30 Mibelle AG Cosmetics Isoflavon-Aglykone enhaltende Hautbehandlungsmittel
MXPA03007609A (es) 2001-02-27 2004-06-30 Univ Michigan Uso de inhibidores egfr naturales para evitar efectos secundarios debidos a terapia de retinoide, jabones y otros estimulos que activan el receptor del factor de crecimiento epidermico.
DE10121375B4 (de) 2001-05-02 2014-01-16 Beiersdorf Ag Verwendung von Isoflavonoiden in kosmetischen oder dermatologischen Zubereitungen zur Prophylaxe vor und Behandlung von sensibler Haut
DE10122342A1 (de) 2001-05-09 2002-11-14 Beiersdorf Ag Verwendung von Isoflavonen in kosmetischen oder dermatologischen Zubereitungen
FR2825277B1 (fr) 2001-05-30 2004-10-15 Oreal Composition cosmetique et/ou dermatologique et/ou pharmaceutique contenant au moins un compose ihnibiteur de l'enzime 3, b-hsd
US6597597B2 (en) * 2001-11-13 2003-07-22 Hewlett-Packard Company Low temperature attaching process for MRAM components
BR0313182A (pt) 2002-07-24 2007-07-24 Childrens Hosp Medical Center composições e produtos contendo equol enantiomérico
US8668914B2 (en) 2002-07-24 2014-03-11 Brigham Young University Use of equol for treating skin diseases
AU2002951271A0 (en) 2002-09-06 2002-09-19 Novogen Research Pty Ltd Repair of dna mutagenic damage
WO2004026274A1 (en) 2002-09-23 2004-04-01 Novogen Research Pty Ltd Skin photoageing and actinic damage treatment
US8580846B2 (en) 2002-10-29 2013-11-12 Brigham Young University Use of equol for ameliorating or preventing neuropsychiatric and neurodegenerative diseases or disorders
AU2003286781B2 (en) 2002-10-29 2009-05-21 Brigham Young University Use of equol for treating androgen mediated diseases
EP1740191A4 (en) 2004-04-28 2008-07-30 Univ Brigham Young USE OF EQUOL FOR THE TREATMENT OF SKIN DISEASES
US7528267B2 (en) 2005-08-01 2009-05-05 Girindus America, Inc. Method for enantioselective hydrogenation of chromenes
CN102726683B (zh) 2005-12-06 2015-04-01 大塚制药株式会社 含雌马酚的大豆胚轴发酵物

Similar Documents

Publication Publication Date Title
JP2012021005A5 (enExample)
Jaimes III et al. Plastics and cardiovascular health: phthalates may disrupt heart rate variability and cardiovascular reactivity
CY1119575T1 (el) Ενωσεις υποκατεστημενης βενζαλδεϋδης και μεθοδοι για τη χρηση τους στην αυξηση της οξυγονωσης του ιστου
EP2205231A1 (en) Pharmaceutical compositions of 5-hydr0xytrypt0phan and serotonin-enhancing compound
BR112013025517A2 (pt) uso de 2,3-diidroimidazo[1,2-c]quinazolinas substituídas
JP6403726B2 (ja) ブプレノルフィンおよびμ−オピオイド受容体アンタゴニストの組成物
JP2015514104A5 (enExample)
JP2010530431A5 (enExample)
WO2012087742A3 (en) Methods and compositions suitable for managing blood glucose in animals
WO2009102962A2 (en) Combination of alpha 7 nicotinic agonists and antipsychotics
JP2011500690A5 (enExample)
RU2012134510A (ru) Применение агента, обладающего модифицирующими свойствами в отношении гормонов надпочечников
JP2016510326A5 (enExample)
JP2013522230A5 (enExample)
JP2018526407A5 (enExample)
BR112012016783A2 (pt) "usos do composto de naltrexona ou sal farmaceuticamente aceitável da mesma a bupropiona ou sal farmaceuticamente aceitável da mesma ou de composição dos mesmos e métodos para proporcionar terapia"
JP2014513065A5 (enExample)
JP2011046708A5 (enExample)
Holder et al. The importance of biological sex in cardiac cachexia
CA2721739C (en) Drug combination and its use in the treatment of muscle loss
Li et al. Oleanolic acid protects against diabetic cardiomyopathy via modulation of the nuclear factor erythroid 2 and insulin signaling pathways
JP2014513121A5 (enExample)
JP2011157350A (ja) 液状組成物
JP2013533305A5 (enExample)
JP2011500731A5 (enExample)